Provided by Tiger Trade Technology Pte. Ltd.

iShares U.S. Healthcare ETF

71.35
+0.57500.81%
Volume:127.40K
Turnover:9.07M
Market Cap:3.72B
PE:6.42
High:71.42
Open:71.29
Low:70.93
Close:70.77
52wk High:74.59
52wk Low:56.44
Shares:52.20M
Float Shares:52.20M
Volume Ratio:0.17
T/O Rate:0.24%
Dividend:0.81
Dividend Rate:1.14%
EPS(TTM):11.10
EPS(LYR):3.06
ROE:6.01%
ROA:0.87%
PB:1.33
PE(LYR):23.32

Loading ...

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

Eli Lilly Announces R$ 0.2 Per Unit Dividend for 3Q 2026 BDRs

Reuters
·
Sep 14

Biofrontera announces FDA approval of Ameluz supplemental new drug application

TIPRANKS
·
Sep 14

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid AI Pullback

MT Newswires Live
·
Sep 14

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live
·
Sep 14

Evercore ISI Remains a Buy on UnitedHealth (UNH)

TIPRANKS
·
Sep 14

U.S. Stocks on the MOVE-US Energy Stocks, Baldwin, Johnson & Johnson

Reuters
·
Sep 14

J&J - Jnj Reports Rybrevant Plus Chemotherapy Extends Pfs2 by 10.8 Months in Nsclc

THOMSON REUTERS
·
Sep 14

Johnson & Johnson’s Rybrevant® (Amivantamab-Vmjw) Plus Chemotherapy Delivers Longest Reported Median Overall Survival in Egfr Exon 20 Insertion Mutation-Positive Lung Cancer

THOMSON REUTERS
·
Sep 14

J&J - Jnj Reports no New Safety Signals for Rybrevant Plus Chemotherapy in Nsclc Study

THOMSON REUTERS
·
Sep 14

Scholar Rock Wins FDA Approval for SMA Therapy

TIPRANKS
·
Sep 14

Potential Buyer Emerges for Johnson & Johnson's Orthopedics Unit

Deep News
·
Sep 14

Scholar Rock price target raised to $84 from $76 at BMO Capital

TIPRANKS
·
Sep 14

Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell

MT Newswires Live
·
Sep 14

Perspective Therapeutics Partners with Merck to Test [212Pb]PSV359 with Keytruda in FAP-Α-Positive Solid Tumors

Reuters
·
Sep 14

Perspective Therapeutics, - Co Sponsors Study; Merck Provides Pembrolizumab at no Cost

THOMSON REUTERS
·
Sep 14

Johnson & Johnson reports PAPILLON study meets primary endpoint

TIPRANKS
·
Sep 14

Market Chatter: Apollo Global in Talks to Buy J&J Orthopedics Unit for $20 Billion

MT Newswires Live
·
Sep 14

One State's Battle to Stop People from Taking Unapproved Weight-Loss Drugs

Dow Jones
·
Sep 14

Nanobiotix announces updated safety, efficacy data from JNJ-1900 study

TIPRANKS
·
Sep 14